Clinical Research Directory

Inclusion Criteria: * All patients must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy. * Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation. * Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI, or ultrasound. Preoperative imaging is not mandatory for study enrollment. * Patients may have received prior systemic chemotherapy. Such therapy must have been completed at least 5 years prior to study entry and the patient has no evidence of disease subsequent to such therapy. Patients must not have received neoadjuvant chemotherapy for the present disease. * Patients must have GOG performance status 0, 1, or 2. * Patients must have an estimated survival greater than or equal to 3 months * Patients must have signed an approved informed consent and HIPAA authorization. Exclusion Criteria: * Patients with clinical evidence of disease beyond the uterus, including presence of suspicious aortic or inguinal nodes on imaging or clinical exam. * Patients who have received previous vaginal, pelvic, or abdominal irradiation. * Patients who received chemotherapy directed at the present disease. * Patients who have circumstances that will not permit completion of this study or the required follow-up. * Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of surgical lymph node assessments. * Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years. * Patients with GOG Performance Grade of 3 or 4.